Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3130752 | 0.86 | GAA (0.53) | GAAKDM4EMAPTALDH1A1RAB9A | |
| SCHEMBL4440700 | 0.83 | KDM4E (0.51) | GAAKDM4EMAPTALDH1A1PKM | |
| SCHEMBL3914044 | 0.81 | THRA (0.50) | GAAMAPTALDH1A1RAB9APKM | |
| SCHEMBL8947150 | 0.80 | GAA (0.67) | GAAKDM4EMAPTALDH1A1RAB9A | |
| SCHEMBL3913177 | 0.79 | THRA (0.45) | GAAMAPTALDH1A1RAB9APKM | |
| SCHEMBL3911770 | 0.78 | MEN1 (0.68) | GAAKDM4EMAPTALDH1A1RAB9A | |
| SCHEMBL5278322 | 0.77 | CYP3A4 (0.44) | GAAKDM4EMAPTALDH1A1PKM | |
| SCHEMBL3909800 | 0.77 | ALDH1A1 (0.39) | GAAKDM4EMAPTALDH1A1RAB9A | |
| SCHEMBL8947103 | 0.76 | KMT2A (0.60) | GAAMAPTPKMPOLBMEN1 | |
| SCHEMBL11280567 | 0.76 | MEN1 (0.48) | GAAKDM4EMAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2009-12-24 | — | — | US | disclosed |
| EP-2024336-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128492-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318514-A1 | Novel Pharmaceutical Compositions | TSHR, TRHR, THRA | GAA 3977/4885KDM4E 1775/4885MAPT 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.